Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice
- 1 April 2004
- Vol. 34 (4), 656-664
- https://doi.org/10.1016/j.bone.2003.12.006
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in RatsJournal of Bone and Mineral Research, 2003
- Adeno‐associated virus–mediated osteoprotegerin gene transfer protects against particulate polyethylene–induced osteolysis in a murine modelArthritis & Rheumatism, 2002
- Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritisArthritis & Rheumatism, 2002
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- Immediate and Long-Term Safety of Recombinant Adeno-associated Virus Injection into the Nonhuman Primate MuscleMolecular Therapy, 2001
- Update on alendronate for osteoporosis: once-weekly dosingExpert Opinion on Pharmacotherapy, 2001
- The Effect of a Single Dose of Osteoprotegerin in Postmenopausal WomenJournal of Bone and Mineral Research, 2001
- Isolation of Highly Infectious and Pure Adeno-Associated Virus Type 2 Vectors with a Single-Step Gravity-Flow ColumnHuman Gene Therapy, 2001
- Perimenopausal bone density screening—will it help prevent osteoporosis?Maturitas, 1997
- Cloning of infectious adeno-associated virus genomes in bacterial plasmidsGene, 1983